secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2024-01-22T23:59:59+00:00
Accession:  0001104659-24-005351
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion prices $85.1M public offering of 56.7M shares at $1.50; underwriters fully exercise option
--------------------------------------------------------------------------------

- Offering of 56,700,000 shares priced at $1.50 per share; gross proceeds ~$85.1M.
- Underwriters fully exercised option for additional 8,505,000 shares at same price.
- Net proceeds expected to be ~$90.8M after underwriting discount and expenses.
- Closing expected Jan 23, 2024; Jefferies LLC sole book-running manager.
- Proceeds to fund commercialization of NEXLETOL/NEXLIZET, R&D, and working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000110465924005351/0001104659-24-005351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000110465924005351/tm243774d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-005351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer